Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cervical Cancer

Cervical Cancer

44 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cervical Cancer

163 trials tracked for Cervical Cancer: 32 in phase 3 or 4 and 15 with published results. The most-cited published study has 1502 citations.

163Trials tracked
32Phase 3 & 4
0Recruiting
15With published results
Phase distribution
Phase 4 5 Phase 3 27 Phase 2 63 Phase 1 14 Other / NA 54
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,502 cited
  2. Phase 3 Study of Cemiplimab in Adults With Cervical Cancer Completed · 455 cited
  3. Phase 3 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) Completed · 411 cited
  4. Phase 3 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Completed · 375 cited
  5. Phase 3 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Completed · 281 cited
  6. Phase 3 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Completed · 205 cited
Show 44 more trials
  1. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 195 cited
  2. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 94 cited
  3. Phase 3 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed · 43 cited
  4. Phase 3 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Completed · 40 cited
  5. Phase 3 Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls Completed · 23 cited
  6. Phase 3 Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial Completed · 10 cited
  7. Phase 4 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed · 8 cited
  8. Phase 3 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Completed · 4 cited
  9. Phase 3 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) Completed · 4 cited
  10. Phase 4 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Completed
  11. Phase 4 Alternate Dosing Schedules Study for HPV Vaccine Completed
  12. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  13. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  14. Phase 3 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer Completed
  15. Phase 3 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Completed
  16. Phase 3 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed
  17. Phase 3 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Completed
  18. Phase 3 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Completed
  19. Phase 3 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Completed
  20. Phase 3 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed
  21. Phase 3 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed
  22. Phase 3 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) Completed
  23. Phase 3 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed
  24. Phase 3 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed
  25. Phase 3 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed
  26. Phase 3 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Completed
  27. Phase 2 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Completed
  28. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  29. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  30. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  31. Phase 2 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed
  32. Phase 2 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy Completed
  33. Phase 2 Irinotecan Study For Cervical Cancer Completed
  34. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  35. Phase 2 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Completed
  36. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  37. Phase 2 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed
  38. Phase 2 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer Completed
  39. Phase 2 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed
  40. Phase 2 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Completed
  41. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  42. Phase 2 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive Completed
  43. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  44. Phase 2 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed

Showing the 50 most-cited and recently-updated of 163 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cervical Cancer: what the trials found

Pembrolizumab has demonstrated significant improvements in progression-free survival (PFS) for cervical cancer patients. In one study, PFS was significantly higher compared to the control group as assessed by both investigator and blinded independent central review (BICR) 1. Another trial confirmed superior outcomes for Pembrolizumab across various cohorts, including those with a Programmed Cell Death-Ligand 1 (PD-L1) combined positive score (CPS) of ≥1 or ≥10 11.

Cemiplimab showed statistically significant improvements in both overall survival (OS) and progression-free survival (PFS) compared to standard treatments, with notable benefits observed specifically within the squamous cell carcinoma (SCC) population 9. Tisotumab vedotin also demonstrated superior OS, PFS, and confirmed objective response rates (ORR) compared to alternative therapies 13.

Several vaccines have been evaluated for cervical cancer prevention. Quadrivalent HPV vaccines (types 6, 11, 16, and 18) were shown to produce high seropositivity for types 16 and 18 at 36 months 17, while the 9vHPV vaccine achieved 100% seroconversion across multiple HPV types by month 7 19. Other vaccines including V501 [4, 18] and V503 15 demonstrated high geometric mean titers (GMTs) for anti-HPV antibodies.

Chemotherapeutic agents such as Carboplatin [12, 21] and Cisplatin [14, 20] are established in the treatment landscape. Additionally, standard radiation therapy was evaluated regarding toxicity; while some differences were noted in acute gastrointestinal and urinary toxicity scores, the percentage of patients with high-grade GI toxicity did not differ significantly from controls 10.

Recent results — preliminary, needs further review

  • TA-CIN (arm) is currently under investigation in a Phase 1 trial 2.

For the clinician treating this condition

  • Pembrolizumab and Cemiplimab are supported by evidence showing significant improvements in progression-free survival and overall survival [1, 9, 11].
  • Tisotumab vedotin is associated with superior objective response rates and progression-free survival compared to standard treatments 13.
  • Multiple HPV vaccines (including quadrivalent and 9vHPV) demonstrate high seroconversion and immunogenicity against major oncogenic types [17, 19].

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AI Colposcopy Aid Shows High Accuracy, Triage Evidence Lags
OB/GYN & Women's Health Meta-analysis
AI Colposcopy Aid Shows High Accuracy, Triage Evidence Lags AI Tools Show Promise in Cervical Cancer Screening and Triage
Meta-analysis finds AI diagnostic assistance during colposcopy most mature (AUC 0.94), but triage of hrHPV-positive women lacks evidence.
Artificial intelligence tools show high accuracy in helping doctors identify cervical cancer during certain stages of the screening and tria…
Sep 1, 2026
Malaria presence at vaccination reduces HPV16 and HPV18 antibody levels in two-dose arms
Pediatrics RCT
Malaria presence at vaccination reduces HPV16 and HPV18 antibody levels in two-dose arms Malaria Presence Linked to Lower HPV Vaccine Antibody Levels
This randomized controlled trial of 930 HIV-negative Tanzanian schoolgirls found that malaria presence at vaccination was associated with lo…
A study in Tanzania found that malaria may lower certain antibody responses in girls receiving two doses of the HPV vaccine.
Aug 30, 2026
Brucea javanica oil emulsion reduces chemoradiotherapy adverse effects and improves immune markers in cervical cancer
Oncology Meta-analysis
Brucea javanica oil emulsion reduces chemoradiotherapy adverse effects and improves immune markers in cervical cancer Brucea javanica Oil May Reduce Side Effects of Cervical Cancer Treatment
This meta-analysis of 372 patients indicates that Brucea javanica oil emulsion (BJOE) significantly reduces treatment-related side effects l…
A review suggests that Brucea javanica oil may reduce nausea and other side effects for patients undergoing cervical cancer treatment.
Frontiers Aug 26, 2026
VaIN recurrence rates reach up to 80% within 2-5 years following hysterectomy for cervical cancer
Oncology Sys. Review
VaIN recurrence rates reach up to 80% within 2-5 years following hysterectomy for cervical cancer High recurrence rates for vaginal precancerous lesions after hysterectomy
This systematic review examines the epidemiology, risk factors, and management of vaginal intraepithelial neoplasia (VaIN) in patients post-…
Women who have had a hysterectomy for cervical cancer face high recurrence rates of vaginal precancerous lesions within five years.
Frontiers Aug 22, 2026
Community governance models for nutrition-oriented care aim to reduce survival disparities across multiple cancers
Allergy & Immunology Sys. Review
Community governance models for nutrition-oriented care aim to reduce survival disparities across multiple cancers Community governance can improve nutrition care for cancer patients
This mini review explores the role of community governance in integrating nutritional support into oncology services for breast, cervical, o…
Newer policy models aim to bridge the gap in nutrition care, helping women with various cancers access better food security and support.
Frontiers Aug 18, 2026
Multifaceted barriers and technological opportunities impact cervical cancer care access in sub-Saharan Africa
Primary Care & Family Medicine Sys. Review
Multifaceted barriers and technological opportunities impact cervical cancer care access in sub-Saharan Africa Barriers to cervical cancer care in sub-Saharan Africa identified
This narrative review of 38 studies identifies individual, community, and health-system level barriers to cervical cancer care in sub-Sahara…
New research highlights how personal beliefs, community norms, and weak health systems create hurdles for people seeking cervical cancer car…
Frontiers Aug 18, 2026
Vaginal microbiota metabolites tied to cervical cancer progression, prognosis, and potential therapy
OB/GYN & Women's Health Sys. Review
Vaginal microbiota metabolites tied to cervical cancer progression, prognosis, and potential therapy Vaginal bacteria products may influence cervical cancer growth and progression
This narrative review synthesizes evidence linking vaginal microbiota metabolites to cervical cancer occurrence, progression, and prognosis.…
New research suggests that chemicals produced by vaginal bacteria play a key role in how cervical cancer develops and spreads.
Frontiers Aug 15, 2026
Scoping review protocol maps technology and barriers to cervical cancer screening uptake
Oncology Sys. Review
Scoping review protocol maps technology and barriers to cervical cancer screening uptake New Plan to Use Technology for Cervical Cancer Screening
This scoping review protocol outlines a planned synthesis of evidence on technological interventions, knowledge, and barriers affecting cerv…
A new research plan aims to use mobile health and telemedicine tools to help more women find out about and access cervical cancer screenings…
Frontiers Aug 8, 2026
Theory-based education significantly increases cervical cancer screening uptake across high and middle-income settings
Oncology Meta-analysis
Theory-based education significantly increases cervical cancer screening uptake across high and middle-income settings Tailored education significantly increases cervical cancer screening rates
This meta-analysis of 12 trials found that theory-based education, incorporating behavioral frameworks and culturally tailored formats, sign…
Specialized, community-based education programs can significantly increase the number of women who get screened for cervical cancer.
Aug 7, 2026
Three-dose HPV vaccine regimens provide highest seroconversion rates and protection against persistent infection
Allergy & Immunology Meta-analysis
Three-dose HPV vaccine regimens provide highest seroconversion rates and protection against persistent infection Three Dose HPV Vaccine Shows Highest Protection Against Infection
This network meta-analysis evaluates different HPV vaccine dose schedules (1D, 2D, and 3D) for females aged 9 to 26 years. The study finds t…
A review of vaccine data shows that a three-dose schedule provides the highest protection against certain HPV infections for girls and young…
Frontiers Aug 6, 2026
Self-collected HPV tests detect 81% to 88.6% of high-grade cervical lesions
Oncology Meta-analysis
Self-collected HPV tests detect 81% to 88.6% of high-grade cervical lesions Self-collected HPV tests detect most cervical cancer cases
This meta-analysis assessed the diagnostic accuracy of HPV testing using self-collected urine and vaginal specimens for detecting high-grade…
Self-collected urine and vaginal samples catch most high-grade cervical lesions, making screening easier and more private.
Aug 6, 2026
Immune checkpoint inhibitors show higher rates of high-grade immune-related adverse events in cervical cancer
OB/GYN & Women's Health Meta-analysis
Immune checkpoint inhibitors show higher rates of high-grade immune-related adverse events in cervical cancer Immune checkpoint inhibitors show specific safety risks in cervical cancer
This meta-analysis of 3302 patients with cervical cancer evaluated the safety profile of immune checkpoint inhibitors (ICIs) compared to sta…
New analysis shows that while some side effects of immune checkpoint inhibitors are similar to standard care, certain high grade immune reac…
Aug 2, 2026

Questions about Cervical Cancer

How does innate immune recognition affect the progression of Cervical Cancer and HPV?

HPV evades innate immune detection by suppressing PRR signaling and NLRP3 inflammasome, enabling persistent infection and cervical cancer progression.

Full answer →